Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

NDA submitted to the US FDA for ziftomenib in adult patients with R/R AML with NPM 1 mutation

April 16, 2025

Ph 1/2a CTA Approval Granted to Evaluate ITOP1 in Early-Stage Esophageal Cancer

April 15, 2025

FDA Clears Second IND Application to Initiate Ph 1 Trial of CER-1236 in Solid Tumors

April 15, 2025

FDA IND Clearance to Initiate Ph 1 Trial for CVHNLC in Squamous NSCLC

April 15, 2025

FDA Clears IND Application for Ph 1 Trial of RB-164 for Hematologic and Solid Malignancies

April 8, 2025

FDA clears IND application for CVHNLC targeting squamous NSCLC

April 8, 2025

FDA clears IND application for ALX2004 for the treatment of EGFR-expressing solid tumors

April 8, 2025

Ph 3 Study Design Finalized with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer

April 2, 2025

Positive CHMP Opinion for the SC Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications

April 2, 2025

NMPA Breakthrough Therapy Designation for IBI363 in Melanoma

April 2, 2025

FDA Clears IND Application for Ph 1 Trial of RB-164 for Hematologic and Solid Malignancies

April 2, 2025

US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma

April 2, 2025

FDA Clears NDA to Initiate Ph 1 Clinical Trial of CER-1236 in Solid Tumors

April 2, 2025

Positive CHMP Opinion for Neoadjuvant Opdivo + Chemo Followed by Surgery and Adjuvant Opdivo for Resectable NSCLC in Patients with Tumor Cell PD-L1 Expression ≥1%

April 2, 2025

Calquence plus chemoimmunotherapy recommended for approval in the EU by CHMP for 1L MCL

April 2, 2025

FDA Approved Compassionate Use Treatment with Namodenoson in a Pancreatic Cancer Patient

March 26, 2025

FDA Orphan Drug Designation for HLX22/AC101 in Gastric Cancer

March 26, 2025

Second DSMB Issues Positive Recommendation to Continue Bria-IMT Ph 3 Study in Metastatic Breast Cancer

March 26, 2025

Azer-cel granted FDA Fast Track Designation in DLBCL

March 26, 2025

FDA Clears IND Application for Tumor-Associated Antigen Vaccine EVM14

March 26, 2025

FDA approves IND application to initiate Oncorella-1 Ph 1/2 trial of ONC175 

March 18, 2025

FDA Clears IND Application for Combination of Versamune® MUC1 and PDS01ADC to Treat Metastatic CRC

March 18, 2025

Update relating to Resminostat’s (Kinselby) Marketing Authorisation Application announced

March 18, 2025

EU authorises CTA to initiate VIDAR-1 Ph 1/2 umbrella trial in patients with mutated KRAS-positive advanced pancreatic cancer

March 18, 2025

SKB445 Receives IND Approval in solid tumors from NMPA in China

March 18, 2025
Page1 Page2 Page3 Page4 … Page31

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.